CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that Sirtris Scientific Advisory Board member and leading academic in the sirtuin field, Eric M. Verdin, M.D., published a review in Molecular Cell entitled “AROuSing SIRT1: Identification of a novel endogenous SIRT1 activator.”
